S L Tunis

Summary

Affiliation: Eli Lilly and Company
Country: USA

Publications

  1. ncbi request reprint Reliability, validity, and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol
    S L Tunis
    Health Outcomes Evaluation Group, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Med Care 37:678-91. 1999
  2. ncbi request reprint Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia
    S L Tunis
    Health Outcomes Evaluation Group, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis 46285, USA
    J Clin Psychiatry 60:38-45; discussion 46. 1999
  3. ncbi request reprint Designing naturalistic prospective studies of economic and effectiveness outcomes associated with novel antipsychotic therapies
    S L Tunis
    Eli Lilly and Company, Indianapolis, IN, USA
    Value Health 3:232-42. 2000

Collaborators

Detail Information

Publications3

  1. ncbi request reprint Reliability, validity, and application of the medical outcomes study 36-item short-form health survey (SF-36) in schizophrenic patients treated with olanzapine versus haloperidol
    S L Tunis
    Health Outcomes Evaluation Group, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    Med Care 37:678-91. 1999
    ..Schizophrenia leads to impairments in mental, social, and physical functioning, which should be included in evaluations of treatment...
  2. ncbi request reprint Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia
    S L Tunis
    Health Outcomes Evaluation Group, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis 46285, USA
    J Clin Psychiatry 60:38-45; discussion 46. 1999
    ..These findings suggest that patient-centered measures of functioning such as the SF-36 are an important component of the evaluation of the cost-effectiveness of novel treatments for schizophrenia...
  3. ncbi request reprint Designing naturalistic prospective studies of economic and effectiveness outcomes associated with novel antipsychotic therapies
    S L Tunis
    Eli Lilly and Company, Indianapolis, IN, USA
    Value Health 3:232-42. 2000
    ..Cost-effectiveness studies of novel antipsychotic medications, particularly those with naturalistic designs, will increase in importance as the use of these second-generation agents continues to expand...